Suzhou Zelgen Biopharmaceuticals Co.,Ltd.(688266),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

688266 Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Noon Closed 04-29 11:29:53

102.23

+1.02

+1.01%

High103.26	Low100.15	Vol1.22M
Open100.15	D1 Closing101.21	Amplitude3.07%
Mkt Cap27.09B	Tradable Cap27.09B	Total Shares265.00M
T/O124.00M	T/O Rate0.46%	Tradable Shares265.00M
P/B21.85	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd.","latestPrice":102.23,"timestamp":1745897393000,"preClose":101.21,"halted":0,"volume":1223004,"delay":0,"changeRate":0.0101,"floatShares":265000000,"shares":265000000,"eps":-0.4783,"marketStatus":"Noon Closed","change":1.02,"latestTime":"04-29 11:29:53","open":100.15,"high":103.26,"low":100.15,"amount":124000000,"amplitude":0.0307,"askPrice":102.23,"askSize":2,"bidPrice":102.1,"bidSize":30,"shortable":0,"etf":0,"ttmEps":-0.4783,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745902800000},"marketStatusCode":3,"adr":0,"adjPreClose":101.21,"symbolType":"stock_kcb","openAndCloseTimeList":[[1745890200000,1745897400000],[1745902800000,1745910000000]],"highLimit":111.33,"lowLimit":91.09,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":21.85,"roa":"--","roe":"--","epsLYR":-0.52,"committee":0.323944,"marketValue":27061000000,"turnoverRate":0.0046,"status":0,"floatMarketCap":27061000000},"requestUrl":"/m/hq/s/688266/wiki","defaultTab":"wiki","newsList":[{"id":"2529250842","title":"Zelgen Biopharma Gets Nod to Trial Small Cell Cancer Drug Combination; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529250842","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529250842?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 15:04","pubTimestamp":1745219053,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration approved Suzhou Zelgen Biopharmaceuticals'  application to conduct clinical trials on a drug combination for small cell cancer, according to a Monday filing on the Shanghai Stock Exchange.The pharmaceutical company will hold trials for injectable ZG006 in combination with PD-1/PD-L1 immune checkpoint inhibitors, the filing said.The company's shares jumped over 5% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2529841573","title":"Zelgen Biopharmaceuticals' Loss Narrows in 2024; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529841573","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529841573?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 14:05","pubTimestamp":1745215555,"startTime":"0","endTime":"0","summary":"Suzhou Zelgen Biopharmaceuticals'  net loss attributable to shareholders in 2024 narrowed to 137.8 million yuan or 0.52 yuan per share from 278.6 million yuan or 1.09 yuan per share in the previous year, according to a Shanghai Stock Exchange disclosure on Saturday.The Chinese biopharmaceutical company's operating income jumped 38% to almost 533 million yuan from 386.4 million yuan a year earlier, the disclosure said.The company's shares jumped less than 5% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2512185967","title":"Zelgen Biopharmaceuticals to Trial Biliary Tract Cancer Drug Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2512185967","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512185967?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 13:25","pubTimestamp":1739856305,"startTime":"0","endTime":"0","summary":"Suzhou Zelgen Biopharmaceuticals  will conduct clinical trials into ZG005 for injection in combination with other therapies after receiving the approval of the Chinese drug administration, according to a Shanghai Stock Exchange filing on Tuesday.The drug will be tested with a platinum-containing chemotherapy regimen to treat patients with advanced biliary tract cancer, the biopharmaceutical company said.The company's shares rose more than 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2494839414","title":"Zelgen Biopharma Gets Nod to Trial Cancer Drug Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2494839414","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494839414?lang=en_us&edition=full_marsco","pubTime":"2024-12-26 16:07","pubTimestamp":1735200476,"startTime":"0","endTime":"0","summary":"Suzhou Zelgen Biopharmaceuticals  will conduct clinical trials on a combination of two drugs after obtaining approval from the Chinese drug administration, according to a Shanghai Stock Exchange disclosure on Thursday.The biopharmaceutical company will trial ZG005 injection combined with gecaxitinib hydrochloride tablets as a treatment for advanced solid tumors and relapsed and refractory lymphoma.The company's shares closed over 1% higher.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688266","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","stockEarnings":[{"period":"1week","weight":-0.0407},{"period":"1month","weight":0.031},{"period":"3month","weight":0.5381},{"period":"6month","weight":0.6175},{"period":"1year","weight":0.8953},{"period":"ytd","weight":0.6243}],"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","perCapita":"35139股","boardName":"医药制造业","registeredCapital":"26470万元","compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0068},{"period":"1year","weight":0.0647},{"period":"ytd","weight":-0.0189}],"survey":"　　苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是药品。","serverTime":1745899687154,"listedPrice":33.76,"stockholders":"7533人(较上一季度减少9.75%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd.(688266),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Suzhou Zelgen Biopharmaceuticals Co.,Ltd.(688266) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd.,688266,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票老虎,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票老虎国际,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.行情,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票行情,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股价,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股市,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票价格,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票交易,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票购买,Suzhou Zelgen Biopharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd.(688266),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Suzhou Zelgen Biopharmaceuticals Co.,Ltd.(688266) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction